𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Scribed by Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J. Druker; for the International Randomized Study of Interferon; STI571 (IRIS) Investigators

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
230 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose imatinib for newly diagnosed c
High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patientsβ€”Systematic review and meta-analysis
✍ Anat Gafter-Gvili; Avi Leader; Ronit Gurion; Liat Vidal; Ron Ram; Adi Shacham-Ab πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 319 KB

## Abstract Imatinib at a dose of 400 mg daily is considered frontline treatment in chronic phase chronic myeloid leukemia (CP‐CML). We conducted a systematic review and meta‐analysis of randomized controlled trials comparing frontline treatment with imatinib 400 mg daily versus higher doses (β‰₯600

Dynamics and management of cytopenias as
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
✍ Alfonso QuintΓ‘s-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 160 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw